Products - Psoriasis | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 37 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Bimekizumab for treating active psoriatic arthritis (TA916)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 October 2023
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 June 2023
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 August 2022
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 July 2022
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 October 2021
Bimekizumab for treating moderate to severe plaque psoriasis (TA723)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 September 2021
Risankizumab for treating moderate to severe plaque psoriasis (TA596)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 August 2019
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 April 2019
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 April 2019
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 March 2019
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 October 2018
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 August 2018
Guselkumab for treating moderate to severe plaque psoriasis (TA521)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2018
Brodalumab for treating moderate to severe plaque psoriasis (TA511)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 March 2018
Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 September 2017
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 July 2017
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 May 2017
Ixekizumab for treating moderate to severe plaque psoriasis (TA442)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 April 2017
Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
3 March 2017
Published:
23 September 2009
Ustekinumab for treating active psoriatic arthritis (TA340)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
3 March 2017
Published:
4 June 2015
Apremilast for treating active psoriatic arthritis (TA433)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 February 2017
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 November 2016
Secukinumab for treating moderate to severe plaque psoriasis (TA350)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 July 2015
Golimumab for the treatment of psoriatic arthritis (TA220)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 April 2011
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 August 2010
Adalimumab for the treatment of adults with psoriasis (TA146)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 June 2008
Infliximab for the treatment of adults with psoriasis (TA134)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 January 2008
Etanercept and efalizumab for the treatment of adults with psoriasis (TA103)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 July 2006
Spesolimab for treating generalised pustular psoriasis flares [ID3963]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
CT-P43 (ustekinumab biosimilar) for treating moderate to severe plaque psoriasis [TSID11773]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
ABP-654 (ustekinumab biosimilar) for previously treated moderate to severe plaque psoriasis [TSID11790]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Apremilast for treating moderate to severe plaque psoriasis in people aged 6 to 17 [TSID11921]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Secukinumab biosimilar for treating plaque psoriasis [TSID11992]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC